Determination of the maximal carcinoma/normal skin ratio after HpD or m-THPC administration in Hairless mice (SKH-1) by fluorescence spectroscopy

被引:10
作者
Bossu, E
Padilla-Ybarra, JJ
Notter, D [1 ]
Vigneron, C
Guillemin, F
机构
[1] Univ Nancy 1, Fac Sci Pharmaceut & Biol, Lab Hematol Physiol & Biol Cellulaire, F-54001 Nancy, France
[2] Ctr Alexis Vautrin, Unite Rech Therapie Photodynam, F-54500 Vandoeuvre Les Nancy, France
[3] Univ Nancy 1, Ctr Rech Automat Nancy, CNRS, URA D0821, F-54000 Nancy, France
[4] Inst Natl Polytech Lorraine, F-54500 Vandoeuvre Les Nancy, France
关键词
carcinoma/normal skin ratio; fluorescence spectroscopy; skin carcinomas; three-stage carcinogenesis;
D O I
10.1097/00001813-200002000-00004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The two major steps in our study on the treatment of skin carcinomas by photochemotherapy (PCT) were the development of a skin tumor model in Hairless mice by a chemical carcinogenesis and the use of fluorescence spectroscopy, a semi-quantitative and non-invasive method, in order to determine the time after i.p. injection of photosensitizer when the tumor/normal skin ratio was the highest. A three-step carcinogenesis protocol provided mice bearing carcinomas and these were used to determine the tumor/normal skin ratios of two photosensitizers by fluorescence spectroscopy, Hematoporphyrin derivative (HpD) (5 mg/kg body weight) and m-tetra(hydroxyphenyl) chlorine (m-THPC) (0.3 mg/kg body weight) were injected i.p,, and fluorescence was measured at 1, 4, 8, 12, 24, 48, 72 and 96 h after injection. The best carcinoma/normal skin ratio would be 3.2+/-1.4 for HPD and 2.7+/-2.1 for m-THPC, respectively. The delays required to reach these ratios were 72 h for HpD and 24 h for m-THPC. These results have to be considered with caution due to the high SEs and they must be confirmed by organic extraction, Photodynamic therapy with the same doses of HpD and m-THPC used in this pharmacokinetic study has to be carried out in order to compare the toxicities of the two photosensitizers and to determine which one is the best for this type of tumor. [(C) 2000 Lippincott Williams & Wilkins.].
引用
收藏
页码:85 / 91
页数:7
相关论文
共 34 条
[11]  
GLANZMANN T, 1994, P SOC PHOTO-OPT INS, V2324, P89
[12]  
GOMER CJ, 1990, CANCER RES, V50, P3985
[13]  
Guillemin F, 1995, P SOC PHOTO-OPT INS, V2627, P92, DOI 10.1117/12.228879
[14]   Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues [J].
Heyerdahl, H ;
Wang, I ;
Liu, DL ;
Berg, R ;
AnderssonEngels, S ;
Peng, Q ;
Moan, J ;
Svanberg, S ;
Svanberg, K .
CANCER LETTERS, 1997, 112 (02) :225-231
[15]   EVALUATION OF A NEW PHOTOSENSITIZER, MESO-TETRA-HYDROXYPHENYL-CHLORIN, FOR USE IN PHOTODYNAMIC THERAPY - A COMPARISON OF ITS PHOTOBIOLOGICAL PROPERTIES WITH THOSE OF 2 OTHER PHOTOSENSITIZERS [J].
MA, LW ;
MOAN, J ;
BERG, K .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (06) :883-888
[16]   CORRELATION BETWEEN META(TETRAHYDROXYPHENYL)CHLORIN (M-THPC) BIODISTRIBUTION AND PHOTODYNAMIC EFFECTS IN MICE [J].
MORLET, L ;
VONARXCOINSMANN, V ;
LENZ, P ;
FOULTIER, MT ;
DEBRITO, LX ;
STEWART, C ;
PATRICE, T .
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 1995, 28 (01) :25-32
[17]   In vitro and in vivo spectrofluorometry of a water-soluble meta-(tetrahydroxyphenyl)chlorin (m-THPC) derivative [J].
Morlet, L ;
Vonarx, V ;
Foultier, MT ;
Gouyette, A ;
Stewart, C ;
Lenz, P ;
Patrice, T .
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 1997, 39 (03) :249-257
[18]  
MUKHTAR H, 1991, PHOTODERMATOL PHOTO, V8, P169
[19]   The kinetics of protoporphyrin fluorescence during ALA-PDT in human malignant skin tumors [J].
Orenstein, A ;
Kostenich, G ;
Malik, Z .
CANCER LETTERS, 1997, 120 (02) :229-234
[20]  
Ortega N, 1997, B CANCER, V84, P391